A SIX-WEEK CHEMOTHERAPY REGIMEN FOR RELAPSED LYMPHOMA: EFFICACY, RESULTS AND THE INFLUENCE OF SCALP COOLING (MEETING ABSTRACT)
We have studied a short, weekly chemotherapy regimen in conjunction with scalp cooling as palliative therapy for patients (pts) with relapsed lymphoma. Twenty pts were treated each week for 6 wk with an iv regimen of vincristine 1 mg, epiribicin 30 mg/m2 and dexamethasone 20 mg (VEDEX). Pts had either chlorambucil-resistant low-grade NHL (n=8), recurrent high-grade NHL not suitable for high-dose chemotherapy (n=8) or heavily pretreated recurrent Hodgkin's disease (n=4). Treatment was given at full dose provided the neutrophil count was greater than 1.0 x 10(9)/L and the platelet count greater than 50 x 10(9)/L. If not, treatment was delayed for 1 wk. 15 pts received scalp cooling using the Clinicool Scalp Cooling system. Three pts failed to complete the 6-wk course of treatment due to progressive disease. All other pts derived symptomatic benefit from treatment. 16/20 (80%) pts achieved an objective response to treatment. The remaining pt died of a pulmonary embolism after 2 wk of treatment before response could be assessed. Bone marrow suppression was the only significant toxicity. However, there were no episodes of neutropenic sepsis or bleeding induced by the treatment. The median number of treatment delays was one (range 0-4). None of the pts using the scalp cooler throughout treatment required a wig. All pts who did not receive scalp cooling developed total alopecia. Complete or major control of emesis was achieved in all pts with simple antiemetics. The VEDEX regimen is effective and well tolerated with minimal gastrointestinal toxicity and, in conjunction with effective scalp cooling, appears to be a very attractive treatment package for palliative therapy.
Purohit OP, Coleman RE, Steers JM, Hancok BW
YCRC Dept. of Clinical Oncology, Western Park Hosp., Sheffield, UK
Ann Oncol; 3(Suppl 5):126 1992